Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Elicio Therapeutics (ELTX) Long-Term Debt Issuances (2020 - 2025)

Elicio Therapeutics filings provide 2 years of Long-Term Debt Issuances readings, the most recent being -$10.0 million for Q4 2023.

On a quarterly basis, Long-Term Debt Issuances changed N/A to -$10.0 million in Q4 2023 year-over-year; TTM through Sep 2023 was $10.0 million, a N/A change, with the full-year FY2020 number at $31.2 million, changed N/A from a year prior.
Long-Term Debt Issuances hit -$10.0 million in Q4 2023 for Elicio Therapeutics, down from $10.0 million in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $17.3 million in Q3 2020 to a low of -$10.0 million in Q4 2023.